Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.
CD74
STRO-001
antibody-drug conjugate
non-Hodgkin lymphoma
xenograft models
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
12 01 2023
12 01 2023
Historique:
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been reported in many B-cell non-Hodgkin lymphomas (NHLs) and in multiple myeloma (MM). STRO-001 is a site-specific, predominantly single-species antibody-drug conjugate (ADC) that targets CD74 and has demonstrated efficacy in xenograft models of MM and tolerability in non-human primates. Here we report results of preclinical studies designed to elucidate the potential role of STRO-001 in B-cell NHL. STRO-001 displayed nanomolar and sub-nanomolar cytotoxicity in 88% (15/17) of cancer cell lines tested. STRO-001 showed potent cytotoxicity on proliferating B cells while limited cytotoxicity was observed on naïve human B cells. A linear dose-response relationship was demonstrated
Identifiants
pubmed: 36634212
pii: 28341
doi: 10.18632/oncotarget.28341
pmc: PMC9836384
doi:
Substances chimiques
Immunoconjugates
0
Antibodies, Monoclonal
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-13Références
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8581-5
pubmed: 8397411
Br J Haematol. 2015 Jun;169(5):701-10
pubmed: 25847298
Br J Haematol. 2018 Apr;181(2):215-228
pubmed: 29532919
Blood. 2010 Feb 25;115(8):1530-3
pubmed: 20032504
Future Oncol. 2013 Mar;9(3):355-68
pubmed: 23469971
Ann N Y Acad Sci. 2015 Nov;1358:82-94
pubmed: 26348626
Immunology. 1999 Oct;98(2):296-302
pubmed: 10540230
Annu Rev Med. 2008;59:237-50
pubmed: 18186705
Lab Invest. 2014 Jul;94(7):806-17
pubmed: 24862967
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1269-81
pubmed: 27033518
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Lancet Oncol. 2016 Jun;17(6):e254-e262
pubmed: 27299281
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s
pubmed: 17875789
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
P T. 2010 Mar;35(3):148-57
pubmed: 20442809
Ther Adv Hematol. 2016 Aug;7(4):209-21
pubmed: 27493711
Blood. 2004 Dec 1;104(12):3705-11
pubmed: 15297317
Blood. 2016 Aug 25;128(8):1112-20
pubmed: 27418643
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Oncotarget. 2018 Dec 28;9(102):37700-37714
pubmed: 30701025
J Pathol Clin Res. 2019 Jan;5(1):12-24
pubmed: 30191677
Clin Cancer Res. 2004 Oct 1;10(19):6606-11
pubmed: 15475450
Mol Cancer Ther. 2013 Jun;12(6):968-78
pubmed: 23427296
Am J Hematol. 2016 Nov;91(11):1096-1101
pubmed: 27465588